BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bedford Laboratories Issues Nationwide Voluntary Hospital/User-Level Recall of Leucovorin Calcium Injection


7/5/2012 8:03:23 AM

BEDFORD, Ohio, July 3, 2012 /PRNewswire/ -- Bedford Laboratories today announced a nationwide voluntary hospital/user-level recall for:

Product Description

NDC

Package Size

Lot#/Expiration Date

First Ship Date

Last Ship

Date

Leucovorin Calcium Injection, 500mg SDV Bedford Label

55390-009-01

1 pack

2017620-1/31/2013

2038374-2/28/2013

1/31/2011

5/17/2011

2/24/2011

6/15/2011

Leucovorin Calcium Injection, 500mg SDV NOVA PLUS® Label

55390-826-01

1 pack

2038374A 2/28/2013

5/16/2011

6/29/2011

Please note: This recall is for lots listed in the above table only. No other lots of Leucovorin Calcium Injection are subject to this voluntary recall.

(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO )

This voluntary recall is being conducted due to the discovery of visible crystalline particulate matter in a small number of vials within the lots listed above. The particulate matter has been identified as active drug substance and not foreign material or contamination. Particulate matter has been recognized as a potential health hazard. Adverse reactions may include vein irritation and phlebitis, clinically occult pulmonary granulomas detected at routine autopsy examination, local tissue infarction, severe pulmonary dysfunction, occlusion of capillaries and arteries, anaphylactic shock and death.

Leucovorin Calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin Calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists; the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible; and for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

Notification of the Leucovorin Calcium lots listed above is being sent to customers who have received product from the identified lots. Healthcare practitioners who had received the lot were instructed not to use the product and immediately quarantine it for return. Anyone with questions can contact Bedford Laboratories Client Services at 800-562-4797 between 8 a.m. and 5 p.m. Eastern time, Monday through Friday.

Any adverse reactions experienced with the lot reported in this release should be reported to Bedford Laboratories at 800-521-5169. Adverse reactions or quality problems experienced with the use of this product may also be reported to the FDA's MedWatch Adverse Event Reporting program:

Bedford Laboratories has informed the U.S. Food and Drug Administration (FDA) of its actions and is maintaining ongoing discussions with the agency. This voluntary recall is being conducted with the knowledge of the U.S. FDA.

The discovery was made due to a field product complaint for visible crystalline particulate and discovery of crystalline particulate in a retained sample. To date, there have been no reports of any adverse events for the lots being recalled. Our highest priority is the delivery of safe and effective medicines for the patients who need them.

As is standard practice, and as stated in the Product Package Insert, "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit."

About Bedford Laboratories
Bedford Laboratories, located in Bedford, Ohio, is a division of Ben Venue Laboratories. Bedford Laboratories supplies a selection of critical-care and medically necessary multisource and specialty injectable products to the healthcare marketplace. For more information, please visit http://www.BedfordLabs.com.

About Ben Venue Laboratories, Inc.
Ben Venue Laboratories, Inc. was founded in 1938 and is a leading manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue is located in Bedford, Ohio, where the company employs more than 1,300 people. For more information, visit www.benvenue.com.

SOURCE Bedford Laboratories




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->